Cartesian Therapeutics, Inc. - Common Stock RNAC 深 滬
等待開盤 11-03 09:30:00 美东时间
8.17
+0.060
+0.74%
華盛通- 最 高8.38
- 今 開8.13
- 成交量 3.36万股
- 最 低 8.0901
- 昨 收 8.11
- 總市值 2.12亿
- 52周最高 26.50
- 市盈率 靜 --
- 換手率 0.13%
- 52周最低 7.75
- 委 比 -50.00%
- 總股本 2595.43万
- 歷史最高 840.00
- 量 比 0.11
- 振 幅 3.57%
- 歷史最低 7.75
- 每 手 1
- 風險率 4.17%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Cartesian Therapeutics Announces Leadership Changes
The latest announcement is out from Cartesian Therapeutics ( ($RNAC) ). On Octo...
10-30 19:27
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics granted inducement stock options to two new employees. The first employee received an option to purchase 50,000 shares at $8.85, vesting 25% on October 27, 2026, with full vesting by October 27, 2029. The second employee received an option for 2,650 shares at $8.20, vesting similarly by October 29, 2029. The company, focused on cell therapies for autoimmune diseases, has assets like Descartes-08 in Phase 3 for myasthenia gr...
10-30 11:05
Cartesian Therapeutics Announces Carsten Brunn, Ph.D., Named as Chairman of the Company’s Board of Directors
Cartesian Therapeutics announced that Carsten Brunn, Ph.D., has been appointed as Chairman of the Board, succeeding Carrie S. Cox, who is focusing on other responsibilities. Descartes-08, the Company's lead CAR-T therapy, is in Phase 3 for myasthenia gravis and Phase 2 for lupus erythematosus, with additional trials planned. The Company also has Descartes-15 in Phase 1 for multiple myeloma. Both Brunn and Cox expressed confidence in the Company's...
10-30 11:00
Cartesian Therapeutics to Participate in Upcoming Investor Conferences
<p>Cartesian Therapeutics announced its management will participate in three investor conferences in September 2025. The events include fireside chats at Cantor Global Healthcare Conference and Morgan Stanley’s Annual Healthcare Conference, and a presentation at the H.C. Wainwright Global Investment Conference. Live webcasts and replays will be available on the company’s website. About Cartesian Therapeutics, the Company is focused on cell therap...
08-28 11:00
Cartesian Therapeutics Q2 EPS $0.50 Compared With $0.54 YoY, Sales Total $298.000K
Cartesian Therapeutics (NASDAQ:RNAC) reported quarterly earnings of $0.50 per share which beat the analyst consensus estimate of $(0.82) by 160.98 percent. This is a 7.41 percent decrease over earnings of $0.54 per share
08-07 19:20
AstraZeneca Prepares Showdown With JNJ, Amgen With Phase 3 Win For Myasthenia Gravis Drug Candidate
AstraZeneca's gefurulimab showed clinical benefits and favorable safety in Phase 3 trial for adults with anti-AChR antibody-positive gMG.
07-25 01:08
Wedbush Initiates Coverage On Cartesian Therapeutics with Outperform Rating, Announces Price Target of $38
Wedbush analyst Martin Fan initiates coverage on Cartesian Therapeutics (NASDAQ:RNAC) with a Outperform rating and announces Price Target of $38.
07-09 18:55
Cartesian Therapeutics Holds Annual Stockholders Meeting
Cartesian Therapeutics ( ($RNAC) ) has shared an announcement. On June 13, 2025...
06-16 19:28
Cartesian Therapeutics Announces New Employment Inducement Grants
Cartesian Therapeutics, a clinical-stage biotech company, announced the granting of inducement awards to three new employees, including options to purchase 26,350 shares with an exercise price of $9.98 under its 2018 Employment Inducement Incentive Award Plan. The options vest 25% on June 2, 2026, followed by three equal annual installments, fully vesting by 2029, with a 10-year term. The company is focused on pioneering cell therapy for autoimmu...
06-03 11:05
